{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-04-15",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "country": "United States",
      "city": "Fremont",
      "address_1": "46117 Landing Pkwy",
      "reason_for_recall": "Certain lots of CEA/CD66e Ab2 were produced with a dilution factor of 1:100 instead of the recommended 1:250.",
      "address_2": "",
      "product_quantity": "RB-368-R7 - 30; RB-368-R1 -2",
      "code_info": "Product Code: RB-368-R7; RB368-R1,  Lot Number  368R1407A  368R1407C  368R1407D  368R1407E, all with expiry dates of July 2016.  Product code: RB368-R1,  Lot Number 368R1407B.",
      "center_classification_date": "20160217",
      "distribution_pattern": "Worldwide Distribution - US including CA, NY, GA, MS, PA, MA, TX, KY, AZ. and Internationally to Greece, France, Germany, Singapore and Serbia.",
      "state": "CA",
      "product_description": "CEA / CD66e Ab-2, Product code RB-368-R7, RB-368-R1; 7 ml each.      Description \u0013 Carcinoembryonic antigen (CEA), is synthesized during development in the fetal gut, and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. Antibody to CEA is reportedly useful in identifying the origin of various metastatic adenocarcinomas and in distinguishing pulmonary adenocarcinomas (60-70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+).    This product is intended for qualitative immunohistochemistry with normal and neoplastic formalin-fixed, paraffin-embedded tissue sections, to be viewed by light microscopy.",
      "report_date": "20160224",
      "classification": "Class III",
      "openfda": {},
      "recalling_firm": "Lab Vision Corporation",
      "recall_number": "Z-0815-2016",
      "initial_firm_notification": "Letter",
      "product_type": "Devices",
      "event_id": "73120",
      "termination_date": "20160624",
      "more_code_info": "",
      "recall_initiation_date": "20160118",
      "postal_code": "94538-6407",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "status": "Terminated"
    }
  ]
}